In vitro evaluation of blood coagulation activation and microthrombus formation by a microchannel array flow analyzer

Thrombosis Research

Volumn 114, Issue 3, 2004, Pages 195-203

  Kamada, Haruhiko ^a   Hattori, Kunihiro ^b   Hayashi, Tatsuya ^a   Suzuki, Koji ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Lipopolysaccharide; Microthrombus formation; Mononuclear cell; Platelet; Tissue factor

Indexed keywords

4 (4 AMIDINOPHENOXY)BUTYRYLASPARTYLVALINE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APC; CILOSTAZOL; DILAZEP; FIBRIN; HEPARIN; HIRUDIN; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; SARPOGRELATE; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANALYZER; ARTICLE; ASSAY; BLOOD CLOTTING; BLOOD FLOW VELOCITY; BLOOD FLOWMETRY; BLOOD VESSEL OCCLUSION; CAPILLARY FLOW; CELL ACTIVATION; CONTROLLED STUDY; EVALUATION; HUMAN; HUMAN CELL; MICROTHROMBUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

ANTITHROMBINS; BLOOD COAGULATION TESTS; BLOOD FLOW VELOCITY; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; FLOW CYTOMETRY; FLOW INJECTION ANALYSIS; HUMANS; LIPOPOLYSACCHARIDES; MICROFLUIDIC ANALYTICAL TECHNIQUES; PLATELET ACTIVATION; THROMBOSIS;

EID: 4444220597     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.06.008     Document Type: Article

References (23)

1. Cohen J. The immunopathogenesis of sepsis. Nature. 420:2002;885-891
2. Osterud B. Cellular interactions in tissue factor expression by blood monocytes. Blood Coagul. Fibrinolysis. 6:1995;S20-S25
3. Kirchhofer D., Nemerson Y. Initiation of blood coagulation: the tissue factor/factor VIIa complex. Curr. Opin. Biotechnol. 7:1996;386-391
4. ten Cate H., Schoenmakers S.H., Franco R., Timmerman J.J., Groot A.P., Spek C.A., et al. Microvascular coagulopathy and disseminated intravascular coagulation. Crit. Care Med. 29:2001;S95-S97. [discussion S97-S98]
5. Taylor F.B. Jr. Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants. Crit. Care Med. 29:2001;S78-S89
6. Bea F., Puolakkainen M.H., McMillen T., Hudson F.N., Mackman N., Kuo C.C., et al. Chlamydia pneumoniae induces tissue factor expression in mouse macrophages via activation of Egr-1 and the MEK-ERK1/2 pathway. Circ. Res. 92:2003;394-401
7. Bjerre A., Brusletto B., Ovstebo R., Joo G.B., Kierulf P., Brandtzaeg P. Identification of meningococcal LPS as a major monocyte activator in IL-10 depleted shock plasmas and CSF by blocking the CD14-TLR4 receptor complex. J. Endotoxin Res. 9:2003;155-163
8. Levi M., Keller T.T., van Gorp E., ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc. Res. 60:2003;26-39
9. van der Poll T. Coagulation and inflammation. J. Endotoxin Res. 7:2001;301-304
10. Esmon C.T., Fukudome K., Mather T., Bode W., Regan L.M., Stearns-Kurosawa D.J., et al. Inflammation, sepsis, and coagulation. Haematologica. 84:1999;254-259
11. Vallet B. Microthrombosis in sepsis. Minerva Anestesiol. 67:2001;298-301
12. Chuda Y., Ono H., Ohnishi-Kameyama M., Matsumoto K., Nagata T., Kikuchi Y. Mumefural, citric acid derivative improving blood fluidity from fruit-juice concentrate of Japanese apricot (Prunus mume Sieb. et Zucc). J. Agric. Food Chem. 47:1999;828-831
13. Engelmann B., Luther T., Muller I. Intravascular tissue factor pathway - a model for rapid initiation of coagulation within the blood vessel. Thromb. Haemost. 89:2003;3-8
14. Osterud B., Bjorklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin. Thromb. Hemost. 27:2001;605-617
15. Camerer E., Kolsto A.B., Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb. Res. 81:1996;1-41
16. Hirsh J., Anand S.S., Halperin J.L., Fuster V. Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 103:2001;2994-3018
17. Greinacher A., Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation. 103:2001;1479-1484
18. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344:2001;699-709
19. Minnema M.C., Chang A.C., Jansen P.M., Lubbers Y.T., Pratt B.M., Whittaker B.G., et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood. 95:2000;1117-1123
20. Creasey A.A., Chang A.C., Feigen L., Wun T.C., Taylor F.B. Jr., Hinshaw L.B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J. Clin. Invest. 91:1993;2850-2860
21. Mohri M., Gonda Y., Oka M., Aoki Y., Gomi K., Kiyota T., et al. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis). Blood Coagul. Fibrinolysis. 8:1997;274-283
22. Martinelli I. Risk factors in venous thromboembolism. Thromb. Haemost. 86:2001;395-403
23. Wakefield T.W., Strieter R.M., Prince M.R., Downing L.J., Greenfield L.J. Pathogenesis of venous thrombosis: a new insight. Cardiovasc. Surg. 5:1997;6-15